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Synapse dysfunction and loss represent critical early events in the pathophysiology of
Alzheimer’s disease (AD). While extensive research has elucidated the direct synaptotoxic
effects of Amyloid-β (Aβ) oligomers, less is known about how signaling pathways at
the synapse are affected by Aβ. A better understanding of the cellular and molecular
mechanisms underlying synaptic vulnerability in AD is key to illuminating the determinants
of AD susceptibility and will unveil novel therapeutic avenues. Canonical Wnt signaling
through the Wnt co-receptor LRP6 has a critical role in maintaining the structural and
functional integrity of synaptic connections in the adult brain. Accumulating evidence
suggests that deficient Wnt signaling may contribute to AD pathology. In particular,
LRP6 deficiency compromises synaptic function and stability, and contributes to Aß
production and plaque formation. Here, we review the role of Wnt signaling for synaptic
maintenance in the adult brain and the contribution of aberrant Wnt signaling to
synaptic degeneration in AD. We place a focus on emerging evidence implicating the
LRP6 receptor as an important modulator of AD risk and pathology.
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INTRODUCTION
Neurodegenerative diseases are characterized by progressive deterioration of nerve cell function
and widespread neuronal death. Among them, Alzheimer’s disease (AD) represents the most
common form of dementia, associated with debilitating mental and cognitive decline (Alzheimer’s
Association, 2016). Due to changing demographics and increasing life expectancies, AD is rapidly
rising in prevalence and its economic and social impact on our societies is predicted to soar
in the coming decades (Hebert et al., 2001; Prince et al., 2013; Alzheimer’s Association, 2016).
No disease-modifying treatments are available for AD. Therefore, there is an urgent need to
develop effective therapeutic approaches to halt or slow disease progression. Intense research over
the past decades has begun to reveal the complex mechanistic underpinnings of AD involving
genetic risk, age-related cellular vulnerability and lifestyle factors. However, the molecular and
cellular determinants of AD susceptibility or resilience and the key mechanisms that drive disease
progression remain poorly understood.
AD presents a variety of pathological hallmarks including extracellular aggregations of
amyloid-β (Aβ) protein, intracellular neurofibrillary tangles of tau protein and neuroinflammation
mediated by glial cells. However, the best correlate of cognitive decline in AD patients is synapse
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loss, which occurs during early disease stages and precedes
neuronal death (DeKosky and Scheff, 1990; Terry et al., 1991;
Scheff et al., 1993; DeKosky et al., 1996; Selkoe, 2002). Synaptic
impairments manifest early also in transgenic mouse models of
AD (Knobloch and Mansuy, 2008; Hong et al., 2016a; Viana
da Silva et al., 2016). Therefore, synaptic dysfunction and loss
are key early events in the pathogenesis of AD. Protection of
synapses and/or restoration of synaptic function is an attractive
therapeutic strategy, as it may offer a chance of reversing or
halting cognitive decline before the onset of large-scale and
irreversible neuronal death. Understanding the molecular and
cellular mechanisms that trigger synapse vulnerability in AD is
critical for therapeutic development.
Research into the causes of synaptic degeneration in AD has
focused on the role of soluble oligomers of Aβ protein. Aβ
peptides, derived through enzymatic cleavage of the amyloid
precursor protein (APP), self-aggregate into oligomers which
are widely regarded as the principal pathogenic agents in AD
(McLean et al., 1999; Näslund et al., 2000; Esparza et al., 2013).
Indeed, Aβ oligomers exert a multitude of synaptotoxic effects
(Palop and Mucke, 2010; Ferreira and Klein, 2011; Tu et al.,
2014; Forner et al., 2017). Oligomeric Aβ accumulates at synaptic
sites, impairs synaptic transmission and plasticity, compromises
the structural integrity of dendritic spines and triggers spine
and synapse elimination (Walsh et al., 2002; Hsieh et al., 2006;
Shankar et al., 2008; Koffie et al., 2009; Wei et al., 2010; Pickett
et al., 2016).
Several studies suggest that Aβ also initiates a variety of
downstream events, which lead to the deregulation of key
cellular pathways that control synaptic function and integrity.
For example, Aβ downregulates the receptor tyrosine kinase
EphB2, which is important for NMDA receptor trafficking to
synaptic sites (Cissé et al., 2011; Miyamoto et al., 2016). Aβ also
induces the aberrant re-activation of developmental mechanisms
of synapse elimination, driven by complement proteins and
microglia (Schafer and Stevens, 2010; Stephan et al., 2012;
Hong et al., 2016b). Another downstream target of Aβ is the
Wnt pathway, a key signaling cascade at the synapse. Growing
evidence suggests that deficient Wnt signaling contributes to
synaptic dysfunction and loss during AD pathogenesis. Multiple
Aβ-targeting treatments have failed to produce appreciable
cognitive benefits in AD clinical trials in recent years (Holmes
et al., 2008; Doody et al., 2013, 2014; Vellas et al., 2013;
Salloway et al., 2014). It is therefore critical to understand
the downstream cellular responses to Aβ to identify new
therapeutic targets. Here, we will summarize emerging evidence
that deficient Wnt signaling could contribute to synaptic
degeneration in AD, focusing on the key role of the Wnt
co-receptor LRP6.
Wnt SIGNALING AND SYNAPSE HEALTH
IN THE ADULT BRAIN
Wnt proteins are a family of highly conserved secreted
lipoproteins that activate several intracellular signaling pathways
and control key aspects of development and tissue homeostasis in
all metazoans (Gordon and Nusse, 2006; MacDonald et al., 2009;
Nusse and Clevers, 2017). Wnt signaling plays a vital role in the
nervous system, from embryogenesis to higher brain function in
the adult.
The most extensively studied signaling cascade activated by
Wnts is the canonical or β-catenin pathway, which regulates
the stability of the transcriptional co-activator β-catenin, thereby
controlling the expression of Wnt target genes (Figure 1). Wnt
ligands bind to Frizzled (Fz) receptors and LRP5/6 co-receptors
resulting in the formation of a ternary complex of Wnt, Fz and
LRP5/6 at the cell surface (MacDonald et al., 2009; Clevers and
Nusse, 2012;MacDonald andHe, 2012; Nusse andClevers, 2017).
The downstream signaling cascade from this receptor complex
leads to recruitment of the scaffold protein Dishevelled (Dvl)
to the plasma membrane and inhibition of GSK3β. β-catenin
can then accumulate in the cytoplasm and translocate to the
nucleus, where it regulates the expression of Wnt target genes
in association with TCF/LEF transcription factors (Figure 1A;
Cong et al., 2003; Valenta et al., 2012; Schuijers et al., 2014).
When the pathway is inactive, cytosolic β-catenin is degraded by
a macromolecular destruction complex composed of the scaffold
protein Axin, the tumor suppressor protein APC and the two
constitutively active serine-threonine kinases CK1 and GSK3ß
(Figure 1B).
TheWnt signaling pathway is regulated by a range of secreted
endogenous antagonists, that either modify or sequester Wnt
ligands or modulate Wnt-receptor interactions at the plasma
membrane (Cruciat and Niehrs, 2013). The best characterized
Wnt antagonists are the Dickkopf (Dkk) proteins, a small
evolutionarily conserved family of secreted glycoproteins with
four members in vertebrates, Dkk1–4, (Niehrs, 2006; Cruciat
and Niehrs, 2013). Dkk1 in particular is well characterized
as a major endogenous Wnt antagonist. Dkk1 inhibits Wnt
signaling by binding to the Wnt co-receptor LRP6, preventing
the formation of the Wnt-Fz-LRP6 complex and the activation
of the Wnt cascade (Figure 1B; Bafico et al., 2001; Mao
et al., 2001; Semënov et al., 2001). Thus, increased levels of
Dkk1 would decrease the availability of the LRP6 receptor for
Wnt ligands.
During postnatal brain development, Wnts play an important
role for synapse assembly in the CNS (reviewed in Ille and
Sommer, 2005; Salinas and Zou, 2008; Budnik and Salinas, 2011;
Park and Shen, 2012; Salinas, 2012; Stamatakou and Salinas,
2014). Many Wnt signaling components are also expressed in
the adult mammalian nervous system (Shimogori et al., 2004;
Wayman et al., 2006; De Ferrari et al., 2007; Gogolla et al.,
2009; Sahores et al., 2010; Seib et al., 2013; Zhang et al., 2014).
Accumulating evidence indicates a significant contribution of
Wnt signaling to synapse physiology and stability in the adult
brain.
Wnt signaling is important for synaptic transmission at
mature synapses. Blockade of endogenous Wnts through
sFRP Wnt antagonists, which sequester Wnt ligands in the
extracellular space, reduces glutamatergic neurotransmission in
cultured neurons (Varela-Nallar et al., 2010; Cerpa et al., 2011;
Ciani et al., 2015). In contrast, application of exogenous Wnts
acutely enhances excitatory synaptic transmission in mature
hippocampal neurons (Beaumont et al., 2007; Cerpa et al.,
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FIGURE 1 | The canonical Wnt pathway and the role of the LRP6 receptor. The LRP6 receptor occupies a unique position within the canonical Wnt pathway as it is
involved in both activation and blockade of the cascade. (A) The canonical Wnt cascade is activated by binding of secreted Wnt molecules to the Frizzled (Fz)
receptor and LRP6 co-receptor at the cell surface. The formation of this complex leads to the recruitment of the scaffold protein Dishevelled (Dvl) and
phosphorylation of the LRP6 C-tail by the kinases GSK3 and CK1. Cytoplasmic β-catenin accumulates and then translocates to the nucleus and activates Wnt
target genes. (B) The secreted Wnt antagonist Dickkopf 1 (Dkk1) blocks Wnt signaling by binding to the LRP6 receptor, thereby preventing the formation of the
Wnt-Fz-LRP6 complex. The cytoplasmic destruction complex containing Axin, APC, GSK3 and CK1 phosphorylates β-catenin, targeting it for proteasomal
degradation. Wnt target genes remain repressed.
2008; Avila et al., 2010; Varela-Nallar et al., 2010; Ciani et al.,
2011, 2015). In vivo, genetic deficiency in Wnt7a and Dvl1
results in reduced synaptic vesicle numbers and decreased
transmitter release (Ahmad-Annuar et al., 2006; Ciani et al.,
2015). Therefore, Wnts are required in mature neuronal circuits
for synaptic function.
Wnt signaling also contributes to the structural stability
of established synaptic connections (reviewed in Dickins
and Salinas, 2013). Short-term blockade of canonical Wnt
signaling through the secreted Wnt antagonist Dkk1 induces
the disassembly of excitatory synapses in mature hippocampal
neurons (Purro et al., 2012). Dkk1 decreases the number and
size of pre- and postsynaptic protein clusters through the
rapid dispersal of synaptic components, without affecting cell
viability (Purro et al., 2012). Electron microscopy analyses
show that remaining synapses have smaller active zones and
postsynaptic densities, suggesting that Wnt blockade induces
coordinated shrinkage and elimination of pre- and postsynaptic
sites (Purro et al., 2012). In vivo suppression of Wnt signaling
through inducible expression of Dkk1 in the adult brain of
transgenic mice recapitulates these effects by eliciting synapse
degeneration (Galli et al., 2014; Marzo et al., 2016). In the
striatum, Wnt inhibition by Dkk1 leads to the loss of excitatory
cortico-striatal as well as dopaminergic synapses and reduced
neurotransmission at remaining synapses (Galli et al., 2014).
In the hippocampus, Dkk1 triggers excitatory synapse loss,
accompanied by defects in synaptic plasticity (blocked LTP
and enhanced LTD) and memory function (Marzo et al.,
2016). Synaptic degeneration occurs in the absence of cell
death, indicating that Dkk1-mediated Wnt blockade directly
compromises synapse stability and integrity (Galli et al., 2014;
Marzo et al., 2016). Collectively, these findings demonstrate that
endogenous Wnt signaling is required for synapse stability in the
mature brain.
The physiological relevance of Wnt-regulated synaptic
integrity is underscored by the implication of Wnt signaling
in memory formation (reviewed in Oliva et al., 2013). Several
studies have shown that blockade of Wnt signaling in the
adult brain interferes with memory function. During fear
memory consolidation in the amygdala, a transient increase
in both β-catenin and Wnt target gene expression is observed
(Maguschak and Ressler, 2011). In contrast, local injection
of the Wnt antagonist Dkk1 disrupts memory consolidation
(Maguschak and Ressler, 2011). A separate study similarly
showed that administration of Wnt3a antibody or Wnt
antagonists sFRP1 or Dkk1 block fear memory acquisition and
consolidation, whereas infusion of exogenous Wnt3a enhances
memory formation (Xu et al., 2015). Post-training infusion
of Dkk1 also interferes with memory consolidation in a
hippocampus-dependent object recognition task (Fortress et al.,
2013). In vivo induction of Dkk1 expression in the adult
hippocampus leads to memory deficits in a range of paradigms,
including spatial navigation and fear memory (Marzo et al.,
2016). Together, these studies show that Wnt signaling is
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required for synaptic changes underlying memory formation and
consolidation.
ABERRANT Wnt SIGNALING
CONTRIBUTES TO SYNAPTIC
VULNERABILITY IN AD
Accumulating evidence suggests that aberrant Wnt signaling
plays a role in the pathogenesis of AD (reviewed in De Ferrari
et al., 2014; Inestrosa and Varela-Nallar, 2014; Purro et al., 2014;
Libro et al., 2016; García-Velázquez and Arias, 2017). Multiple
findings indicate that Wnt signaling becomes deregulated in the
context of AD. In brains of familial AD patients, active GSK3β
accumulates, whereas β-catenin levels are reduced (Zhang et al.,
1998; Pei et al., 1999; Kawamura et al., 2001). Dkk1 expression
is increased in brains from AD patients and transgenic AD
mouse models (Caricasole et al., 2004; Rosi et al., 2010). Dkk3,
which is closely related to Dkk1, is also elevated in plasma
and cerebrospinal fluid of AD patients (Zenzmaier et al., 2009).
Moreover, exposure of hippocampal neurons to Aβ leads to
inhibition of Wnt signaling (De Ferrari et al., 2003; Alvarez et al.,
2004). Consistent with these findings, Aß rapidly increases the
levels of the endogenous Wnt antagonist Dkk1 (Purro et al.,
2012). Together, these results indicate a deficiency of Wnt
signaling in the context of AD.
How does perturbation of Wnt signaling influence AD
pathogenesis? Suppression of Wnt signaling by Aß could
decreaseWnt-dependent synaptic stability during the early stages
of AD. Consistent with this hypothesis, short-term exposure of
hippocampal neurons to oligomeric Aβ induces Dkk1 expression
and triggers synapse loss (Purro et al., 2012; Sellers et al.,
2018). Importantly, neutralizing antibodies against Dkk1 protect
synapses from Aβ toxicity (Purro et al., 2012). Interestingly, a
recent study suggests that Dkk1 may signal through its receptor
Kremen1 to mediate Aβ synaptotoxicity (Ross et al., 2018). In
summary, these findings strongly suggest that Dkk1 is involved
in Aß-mediated synapse loss.
To mimic the effect of Aß in vivo, a transgenic mouse
model that inducibly expresses Dkk1 was generated. Inhibition
of endogenous Wnt signaling by Dkk1 in vivo triggers synapse
loss in the striatum and hippocampus (Galli et al., 2014; Marzo
et al., 2016). Hippocampal Dkk1 expression reduces synaptic
transmission, impairs LTP and enhances LTD, and these synaptic
defects are accompanied by memory deficits (Marzo et al., 2016).
Thus, inducible Dkk1 expression in the adult brain mimics
various aspects of Aβ-induced synaptic degeneration. These
findings support the view that suppression of Wnt signaling
downstream of Aβ promotes synaptic destabilization and may
contribute to cognitive decline.
THE LRP6 RECEPTOR AS A KEY
EMERGING LINK BETWEEN Wnt
SIGNALING, SYNAPSE HEALTH AND AD
Activation of the canonical Wnt pathway requires the
cooperation of Wnt/Fz with the single-pass transmembrane
co-receptors LRP5/6, which belong to the extended low-density
lipoprotein receptor (LDLR) family (He et al., 2004; MacDonald
and He, 2012). LRP5 and LRP6 are highly homologous and
display largely overlapping expression patterns, however
LRP6 plays a more influential role and is the best characterized
Wnt co-receptor (MacDonald et al., 2011). LRP6 is key for
Wnt signal transduction, which relies on the phosphorylation
of the LRP6 intracellular domain following Wnt binding
to this co-receptor (He et al., 2004; MacDonald and He,
2012). LRP6 is also the main receptor for the Dkk family of
Wnt secreted antagonists, most notably Dkk1 (Bafico et al.,
2001; Mao et al., 2001; Semënov et al., 2001). Dkk1 disrupts
LRP6 function as a Wnt co-receptor. The LRP6 receptor
therefore occupies a unique position within the Wnt pathway
(Figure 1).
The Role of LRP6 in Embryogenesis and
Synapse Formation
Constitutive knockout of LRP6 is lethal, as LRP6−/− mice die
at birth due to early patterning defects (Pinson et al., 2000).
Loss of function of LRP6 causes severe defects specifically in the
nervous system, including reduced production of granule cells
in the hippocampus, deficiency in thalamic development and
impaired neuronal proliferation in the neocortex (Zhou et al.,
2004a,b, 2006). Therefore, LRP6 plays a critical role during early
development, consistent with its role as a keyWnt receptor in the
canonical Wnt pathway.
LRP6 is also important during synapse formation in the
developing nervous system. Knockdown of LRP6 in young
hippocampal neurons leads to a decrease in the number
of excitatory synapses and impairs spine morphogenesis,
without affecting inhibitory synapses (Sharma et al.,
2013). Similarly, in vivo loss of function of LRP6 in
developing cortical neurons compromises dendritic spine
development, accompanied by a functional impairment
of excitatory postsynaptic currents (Sharma et al., 2013).
LRP6 phosphorylation at residue S1490, which is a key step
during Wnt signal transduction, is required for LRP6-mediated
synaptogenesis (Sharma et al., 2013). Thus, LRP6 has
a key role in Wnt-mediated synapse formation and is
required for excitatory synapse formation during postnatal
development.
LRP6 and Synapse Integrity in the Adult
and Aging Brain
The role of LRP6 in the mature brain was investigated in
a conditional knockout (cKO) model, based on CaMKII-Cre-
driven deletion of LRP6 in principal forebrain neurons (Liu
et al., 2014). LRP6 cKO impairs Wnt signaling and causes
synapse dysfunction and loss in an age-dependent manner.
Spine density, synaptic protein levels, synaptic plasticity and
memory function are normal in young adult cKO mice at
6 months (Liu et al., 2014). However, LRP6 cKO mice at
18–22 months exhibit spine loss in hippocampal and cortical
neurons, impaired LTP maintenance and memory deficits in
fear conditioning tests (Liu et al., 2014). Reduced cell viability
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FIGURE 2 | Potential roles for the LRP6 receptor in several key pathogenic processes in Alzheimer’s disease (AD). Several hallmarks of AD pathology have been
identified and LRP6 dysfunction contributes to these pathogenic processes in multiple different ways: (1) Deficiency in LRP6-mediated Wnt signaling increases
synaptic vulnerability, which could promote synaptic dysfunction and loss in AD; (2) LRP6 regulates amyloid precursor protein (APP) processing and LRP6 loss of
function increases amyloid-β (Aβ) generation and plaque formation; (3) Neuroinflammatory processes also contribute to AD pathology. Neuronal LRP6 deficiency has
a secondary impact on microglia and astrocytes, promoting neuroinflammation and secretion of pro-inflammatory molecules; (4) Lipid metabolism is deregulated in
AD and Apolipoprotein E (ApoE) is a major genetic risk factor for AD. LRP6 could participate in cholesterol transport and may be involved in the internalization of
ApoE-containing lipoprotein particles.
may contribute to these effects (Liu et al., 2014). Thus,
neuronal LRP6 deficiency leads to synaptic dysfunction and loss,
accompanied by cognitive impairment, specifically in the aging
brain (Figure 2, panel 1).
LRP6 and Links to AD
Several studies suggest a link between LRP6 and AD. Through
genome-wide linkage analyses, a broad susceptibility locus for
late-onset AD was identified on chromosome 12, which includes
the region encoding LRP6 (Pericak-Vance et al., 1997; Rogaeva
et al., 1998; Kehoe et al., 1999; Scott et al., 2000; Mayeux et al.,
2002; Myers et al., 2002; D’Introno et al., 2006; Lee et al.,
2008). Follow-up studies associated two LRP6 single-nucleotide
polymorphisms (SNPs) and one alternative splice variant of
LRP6 with an increased risk of late-onset AD (De Ferrari
et al., 2007; Alarcón et al., 2013). These observations establish
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a genetic link between late-onset AD and LRP6. Both the LRP6
14e-Val variant and the LRP6∆3 splice isoform, which skips
exon 3, are associated with reduced activation of Wnt/β-catenin
signaling in HEK293T cells (De Ferrari et al., 2007; Alarcón et al.,
2013).
In human AD brains, LRP6 mRNA and protein levels
are significantly downregulated compared to age-matched
controls (Liu et al., 2014). Concomitant reduction in canonical
Wnt signaling suggests that LRP6-mediated Wnt signaling is
compromised in AD (Liu et al., 2014). LRP6 deficiency promotes
AD pathology as the levels of soluble Aβ40/42 and amyloid plaque
burden are increased in hippocampus and cortex of APP/PSEN1
transgenic mice lacking neuronal LRP6 (Figure 2, panel 2; Liu
et al., 2014). LRP6 cKO also exacerbates memory deficits in this
AD model (Liu et al., 2014). Together, these findings indicate
that LRP6 deficiency—as observed in AD brains—aggravates AD
pathology.
How does LRP6 modulate amyloid pathology? LRP6 can
directly influence the processing of APP (Figure 2, panel 2).
Co-immunoprecipitation assays demonstrated that APP
and LRP6 interact via their extracellular domains (Liu
et al., 2014). Knockdown of LRP6 in an APP-expressing
cell line increases production of Aβ and its by-products,
suggesting that LRP6 downregulation stimulates amyloidogenic
processing of APP. In vivo LRP6 deficiency similarly increases
endogenous Aβ40 and Aβ42 levels, whereas overexpression
of LRP6 leads to reduced production of Aβ40 and Aβ42
(Figure 2, panel 2, Liu et al., 2014). LRP6 may modulate
Aβ production by promoting cell surface localization of
APP (Liu et al., 2014), which favors non-amyloidogenic
processing by α-secretase (Haass et al., 1993; Parvathy et al.,
1999; Carey et al., 2005; Zhang and Song, 2013). These
results suggest that LRP6 interacts with APP to retain it
at the cell surface, thereby suppressing Aβ production.
In contrast, LRP6 deficiency in AD models increases the
amyloidogenic processing of APP, fueling Aβ generation and
plaque formation. Therefore, LRP6 loss of function could be part
of a positive feedback loop leading to the exacerbation of AD
pathology.
LRP6 may also play a role in other AD-relevant processes,
beyond synaptic maintenance and Aβ pathology. First, the
influence of non-neuronal glia cells and aberrant immune
responses are increasingly recognized as important components
of AD pathology (Heneka et al., 2015; Heppner et al., 2015;
Zhang and Jiang, 2015; Bronzuoli et al., 2016; De Strooper
and Karran, 2016). Genetic, clinical and cell biology data
have shown that neuroinflammation driven by microglia and
astrocytes plays a significant causal role in driving and
exacerbating AD pathogenesis (Heneka et al., 2015; Heppner
et al., 2015; Zhang and Jiang, 2015; Bronzuoli et al., 2016).
Mutations in several microglia-associated genes are linked
to late-onset AD, indicating a central role for microglia in
the disease etiology (Jones et al., 2010; Malik et al., 2015;
Villegas-Llerena et al., 2016; Efthymiou and Goate, 2017).
In addition, microglia may contribute to synapse elimination
downstream of Aβ (Paolicelli et al., 2011; Hong et al.,
2016a,b). Intriguingly, postnatal neuronal deletion of LRP6 in
conditional KO mice increases the presence of astrocytes
and microglia in the aging hippocampus and results in the
expression of pro-inflammatory cytokines (Figure 2, panel 3;
Liu et al., 2014). These findings suggest that deficiency
in neuronal LRP6-mediated Wnt signaling could indirectly
promote neuroinflammation during aging, thereby further
fueling AD pathogenesis. LRP6 is also expressed in microglia
and astrocytes (Halleskog et al., 2011; L’Episcopo et al., 2011;
Zhang et al., 2014; Zeisel et al., 2015). However, the role
of LRP6 in glia cells in the context of AD remains to be
studied. Given that astrocytes have important functions in
regulating synaptic transmission and plasticity, they could also
contribute to the synaptic defects observed in early stages of AD.
Future studies on the impact of LRP6-mediated Wnt signaling
on astrocytes could therefore also help to elucidate changes
in the astrocyte-neuron crosstalk at synapses in the context
of AD.
LRP6 deficiency could further contribute to AD pathogenesis
through its role in lipid metabolism (Figure 2, panel 4). As
a member of the extended LDLR receptor family, LRP6 is
involved in LDL uptake and cholesterol clearance (Liu
et al., 2008; Tomaszewski et al., 2009; Go and Mani, 2012;
Ye et al., 2012). Coding-region LRP6 SNP mutations have
been associated with elevated LDL cholesterol levels (Mani
et al., 2007; Liu et al., 2008; Tomaszewski et al., 2009; Go
et al., 2014). Perturbation of lipid metabolism is associated
with AD, as gene network analyses have highlighted altered
lipid and cholesterol metabolism as one of three biological
pathways with a central role in AD etiology (Jones et al.,
2010; Guerreiro et al., 2013; Guerreiro and Hardy, 2014;
Hardy et al., 2014; International Genomics of Alzheimer’s
Disease Consortium (IGAP), 2015; Karch and Goate, 2015;
Efthymiou and Goate, 2017). High cholesterol levels in mid-life
may contribute to AD susceptibility (Notkola et al., 1998;
Kivipelto et al., 2002; Whitmer et al., 2005). The primary
function of the major AD risk gene Apolipoprotein E
(APOE) is in cholesterol transport (Huang and Mahley,
2014), and ApoE-containing lipoproteins bind to all core
members of the LDLR receptor family, to LRP5 and likely
to LRP6 as well (Figure 2, panel 4; Kim et al., 1998;
Magoori et al., 2003; Beffert et al., 2004; Andersen and
Willnow, 2006; Jaeger and Pietrzik, 2008; Guttman et al.,
2010). These observations raise the intriguing possibility
that LRP6 may also be involved in AD pathogenesis
through deregulation of lipid metabolism. Altogether,
these findings highlight the importance of LRP6 function
and LRP6-mediated Wnt signaling for a healthy aging
brain.
CONCLUDING REMARKS
Long-term synaptic integrity and resilience are vital factors
determining the susceptibility to an age-related degenerative
disorder such as AD. Indeed, synaptic degeneration is a key
early event in the pathophysiology of AD, and exciting new
research is shedding more light on important cellular and
molecular mechanisms that underpin synaptic vulnerability.
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Wnt signaling and the Wnt co-receptor LRP6 have a central
role in synapse formation, stability and function. Growing
evidence indicates that deficiency of Wnt signaling contributes
to synapse dysfunction and loss in the adult and aging brain,
fueling the pathogenesis of AD. Increased levels of the Wnt
antagonist Dkk1 or LRP6 loss of function negatively impact
on several key pathogenic processes by inducing synapse
dysfunction and degeneration as well as deficits in LTP
and memory. LRP6 deficiency also promotes Aβ production
and amyloid deposition, stimulates neuroinflammation and
potentially contributes to aberrant lipid metabolism. These
findings point to Dkk1 and LRP6 as important molecular
modulators of AD risk and pathology. Restoring Wnt signaling
and LRP6 function may therefore represent a viable therapeutic
strategy for AD.
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